The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial
- DOI
- 10.1016/j.annonc.2024.11.011
- Published
- 2025-03
- Container
- Annals of Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.annonc.2024.11.011,
title = {The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial},
author = {A. Alvarez Secord and S.N. Lewin and C.G. Murphy and S.C. Cecere and A. Barquín and F. Gálvez-Montosa and C.A. Mathews and G.E. Konecny and I. Ray-Coquard and A. Oaknin and M.J. Rubio Pérez and A. Bonaventura and E.J. Diver and S.-M. Ayuk and Y. Wang and B.R. Corr and V. Salutari},
year = {2025},
journal = {Annals of Oncology},
doi = {10.1016/j.annonc.2024.11.011},
url = {https://doi.org/10.1016/j.annonc.2024.11.011}
}RIS
TY - JOUR TI - The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial AU - A. Alvarez Secord AU - S.N. Lewin AU - C.G. Murphy AU - S.C. Cecere AU - A. Barquín AU - F. Gálvez-Montosa AU - C.A. Mathews AU - G.E. Konecny AU - I. Ray-Coquard AU - A. Oaknin AU - M.J. Rubio Pérez AU - A. Bonaventura AU - E.J. Diver AU - S.-M. Ayuk AU - Y. Wang AU - B.R. Corr AU - V. Salutari PY - 2025 JO - Annals of Oncology DO - 10.1016/j.annonc.2024.11.011 UR - https://doi.org/10.1016/j.annonc.2024.11.011 ER -
APA
Secord, A. A., Lewin, S., Murphy, C., Cecere, S., Barquín, A., Gálvez-Montosa, F., Mathews, C., Konecny, G., Ray-Coquard, I., Oaknin, A., Pérez, M. R., Bonaventura, A., Diver, E., Ayuk, S., Wang, Y., Corr, B., & Salutari, V. (2025). The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial. Annals of Oncology. https://doi.org/10.1016/j.annonc.2024.11.011
Source records
- crossref · retrieved 2026-09-27T00:21:59.119Z